导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -4.73% | 3299/4773 |
| 近一周 | -1.87% | 809/5462 |
| 近一月 | -2.02% | 1131/5421 |
| 近一季 | -2.01% | 1134/5209 |
| 近半年 | -2.52% | 1930/4920 |
| 近一年 | -2.22% | 2989/4366 |
| 近两年 | 32.11% | 2197/2954 |
| 近三年 | 18.86% | 1509/2253 |
| 成立以来 | 14.57% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.45% 4143/4961 |
5.89% 2867/5312 |
- - |
- - |
| 2025 | 15.10% 2572/4813 |
-0.49% 2271/3635 |
2.76% 1375/4076 |
10.66% 3264/4524 |
1.71% 1257/4813 |
| 2024 | 16.66% 782/3463 |
3.32% 595/2808 |
-0.43% 764/3014 |
16.36% 1476/3129 |
-2.54% 2125/3463 |
| 2023 | -9.21% 1133/2656 |
0.64% 1719/2280 |
-4.71% 1262/2385 |
1.56% 298/2515 |
-6.79% 1923/2655 |
| 2022 | -17.17% 558/2207 |
-11.16% 485/1919 |
6.35% 718/2016 |
-13.32% 880/2113 |
1.13% 1375/2208 |
| 2021 | -9.22% 1073/1822 |
-3.12% 761/1255 |
-0.31% 1140/1330 |
-7.72% 1078/1466 |
1.85% 777/1822 |
| 2020 | 19.68% 730/1250 |
-11.70% 847/1028 |
10.05% 777/1067 |
10.30% 564/1164 |
11.65% 528/1184 |
| 2019 | 31.53% 464/1092 |
21.82% 590/754 |
3.11% 60/804 |
-0.30% 591/850 |
5.04% 756/918 |
| 2018 | - - |
- - |
- - |
- - |
-11.59% 322/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏上证50ETF联接C VS. 长安沪深300非周期A(740101) |